Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.

Khanna R, Yu J, Yang X, Moutal A, Chefdeville A, Gokhale V, Shuja Z, Chew LA, Bellampalli SS, Luo S, François-Moutal L, Serafini MJ, Ha T, Perez-Miller S, Park KD, Patwardhan AM, Streicher JM, Colecraft HM, Khanna M.

Pain. 2019 Feb 5. doi: 10.1097/j.pain.0000000000001524. [Epub ahead of print]

PMID:
30933958
2.

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, Jo S, Park M, Yeon SK, Kim S, Kim J, Nam MH, Londhe AM, Kim J, Cho SJ, Cho S, Lee C, Hwang SY, Kim SW, Oh SJ, Cho J, Pae AN, Lee CJ, Park KD.

Sci Adv. 2019 Mar 20;5(3):eaav0316. doi: 10.1126/sciadv.aav0316. eCollection 2019 Mar.

3.

Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission.

Yu J, Moutal A, Dorame A, Bellampalli SS, Chefdeville A, Kanazawa I, Pham NYN, Park KD, Weimer JM, Khanna R.

Mol Neurobiol. 2018 Dec 18. doi: 10.1007/s12035-018-1445-6. [Epub ahead of print]

PMID:
30565051
4.

Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.

Choi JW, Kim S, Park JH, Kim HJ, Shin SJ, Kim JW, Woo SY, Lee C, Han SM, Lee J, Pae AN, Han G, Park KD.

J Med Chem. 2019 Jan 24;62(2):811-830. doi: 10.1021/acs.jmedchem.8b01527. Epub 2018 Dec 20.

PMID:
30540174
5.

First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.

Farag AK, Hassan AHE, Jeong H, Kwon Y, Choi JG, Oh MS, Park KD, Kim YK, Roh EJ.

Eur J Med Chem. 2019 Jan 15;162:161-175. doi: 10.1016/j.ejmech.2018.10.057. Epub 2018 Nov 2.

PMID:
30445265
6.

The Novel Neuroprotective Compound KMS99220 Has an Early Anti-neuroinflammatory Effect via AMPK and HO-1, Independent of Nrf2.

Lee JA, Kim HR, Kim J, Park KD, Kim DJ, Hwang O.

Exp Neurobiol. 2018 Oct;27(5):408-418. doi: 10.5607/en.2018.27.5.408. Epub 2018 Oct 31.

7.

Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB2R affinity.

Hassan AHE, Cho MC, Kim HI, Yang JS, Park KT, Hwang JY, Jang CG, Park KD, Lee YS.

Bioorg Med Chem. 2018 Oct 1;26(18):5069-5078. doi: 10.1016/j.bmc.2018.09.007. Epub 2018 Sep 6.

PMID:
30217464
8.

Mammalian target of rapamycin complex 1 and its downstream effector collapsin response mediator protein-2 drive reinstatement of alcohol reward seeking.

Ben Hamida S, Laguesse S, Morisot N, Park JH, Phuamluong K, Berger AL, Park KD, Ron D.

Addict Biol. 2018 Jul 18. doi: 10.1111/adb.12653. [Epub ahead of print]

9.

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Yeon SK, Choi JW, Park JH, Lee YR, Kim HJ, Shin SJ, Jang BK, Kim S, Bahn YS, Han G, Lee YS, Pae AN, Park KD.

Bioorg Med Chem. 2018 Jan 1;26(1):232-244. doi: 10.1016/j.bmc.2017.11.036. Epub 2017 Nov 24.

PMID:
29198609
10.

Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220.

Lee JA, Son HJ, Choi JW, Kim J, Han SH, Shin N, Kim JH, Kim SJ, Heo JY, Kim DJ, Park KD, Hwang O.

Neurochem Int. 2018 Jan;112:96-107. doi: 10.1016/j.neuint.2017.11.006. Epub 2017 Nov 20.

PMID:
29158022
11.

Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.

Kim T, Son WS, Morshed MN, Londhe AM, Jung SY, Park JH, Park WK, Lim SM, Park KD, Cho SJ, Jeong KS, Lee J, Pae AN.

Eur J Med Chem. 2017 Dec 1;141:240-256. doi: 10.1016/j.ejmech.2017.09.033. Epub 2017 Sep 21.

PMID:
29031071
12.

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R.

Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002.

13.

CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.

Moutal A, Villa LS, Yeon SK, Householder KT, Park KD, Sirianni RW, Khanna R.

Mol Neurobiol. 2018 May;55(5):4403-4416. doi: 10.1007/s12035-017-0653-9. Epub 2017 Jun 28.

14.

Antifungal Activities of Dimeric Sesquiterpenes, Shizukaols C and F, Isolated from Chloranthus japonicus Sieb.

Kang TH, Lee YM, Lee WJ, Hwang EI, Park KD, Choi GJ, Moon JS, Park HY, Kim SU.

J Microbiol Biotechnol. 2017 Jul 28;27(7):1272-1275. doi: 10.4014/jmb.1612.12051.

15.

Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: A novel class of TSPO ligands modulating amyloid-β-induced mPTP opening.

Elkamhawy A, Park JE, Hassan AHE, Pae AN, Lee J, Park BG, Paik S, Do J, Park JH, Park KD, Moon B, Park WK, Cho H, Jeong DY, Roh EJ.

Eur J Pharm Sci. 2017 Jun 15;104:366-381. doi: 10.1016/j.ejps.2017.04.015. Epub 2017 Apr 21.

PMID:
28435076
16.

Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.

Nam MH, Park M, Park H, Kim Y, Yoon S, Sawant VS, Choi JW, Park JH, Park KD, Min SJ, Lee CJ, Choo H.

ACS Chem Neurosci. 2017 Jul 19;8(7):1519-1529. doi: 10.1021/acschemneuro.7b00050. Epub 2017 Mar 30.

PMID:
28332824
18.

Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Moutal A, Eyde N, Telemi E, Park KD, Xie JY, Dodick DW, Porreca F, Khanna R.

Pain Rep. 2016 Jun;1(1). pii: e565.

19.

Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.

Kim T, Yang HY, Park BG, Jung SY, Park JH, Park KD, Min SJ, Tae J, Yang H, Cho S, Cho SJ, Song H, Mook-Jung I, Lee J, Pae AN.

Eur J Med Chem. 2017 Jan 5;125:1172-1192. doi: 10.1016/j.ejmech.2016.11.017. Epub 2016 Nov 9.

PMID:
27855359
20.

Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.

Viswanath AN, Jung SY, Hwang EM, Park KD, Lim SM, Min SJ, Cho YS, Pae AN.

Chem Biol Drug Des. 2016 Dec;88(6):807-819. doi: 10.1111/cbdd.12810. Epub 2016 Jul 27.

PMID:
27346364

Supplemental Content

Loading ...
Support Center